C4 Therapeutics (CCCC) UBS Targeted Protein Degradation Day 2024 summary

Company overview and technology differentiation

• Focused on targeted protein degradation, primarily in oncology, leveraging catalytic efficiency for optimal degrader activity.

• Proprietary tools predict in vivo performance from in vitro data, enhancing candidate selection.

• Large Cereblon Toolkit library enables development of both heterobifunctional (BiDACs) and molecular glue (MonoDACs) degraders.

• Collaborations with Roche, Merck KGaA, and Biogen expand reach beyond oncology and support pipeline advancement.

Pipeline progress and upcoming milestones

• Prioritizing cemsidomide (IKZF1/3 degrader) for multiple myeloma/NHL and CFT1946 (BRAF V600X degrader).

• Initial phase I monotherapy data for CFT1946 and combination/monotherapy data for cemsidomide expected in the second half of the year.

• Delivered a development candidate to Biogen and announced a new collaboration with Merck KGaA.

• Board changes include Ron Cooper as chairman to support transition to a fully integrated biotech.

Cemsidomide program in multiple myeloma and NHL

• Multiple myeloma study includes monotherapy and combination with dexamethasone; expanded cohorts ongoing.

• Data will focus on safety and efficacy across several dose levels, with full characterization using IMWG criteria.

• Lymphoma arm is monotherapy, enrolling a heterogeneous refractory NHL population; safety and efficacy data to be disclosed.

• Efficacy benchmark for NHL is a response rate of at least 30% for high-quality responders.